Evidence of GLP-1-mediated Neuroprotection in an Animal Model of Pyridoxine-induced Peripheral Sensory Neuropathy

Overview

Journal Exp Neurol

Specialty Neurology

Date 2006 Nov 28

PMID 17125767

Citations 85

Authors

TracyAnn Perry

Harold W Holloway

Ananda Weerasuriya

Peter R Mouton

Kara Duffy

Julie A Mattison

Nigel H Greig

Affiliations

Soon will be listed here.

Abstract

Pyridoxine (vitamin B6) intoxicated rodents develop a peripheral neuropathy characterized by sensory nerve conduction deficits associated with disturbances of nerve fiber geometry and axonal atrophy. To investigate the possibility that glucagon-like peptide-1 (7-36)-amide (GLP-1) receptor agonism may influence axonal structure and function through neuroprotection neurotrophic support, effects of GLP-1 and its long acting analog, Exendin-4 (Ex4) treatment on pyridoxine-induced peripheral neuropathy were examined in rats using behavioral and morphometric techniques. GLP-1 is an endogenous insulinotropic peptide secreted from the gut in response to the presence of food. GLP-1 receptors (GLP-1R) are coupled to the cAMP second messenger pathway, and are expressed widely throughout neural tissues of humans and rodents. Recent studies have established that GLP-1 and Ex4, have multiple synergistic effects on glucose-dependent insulin secretion pathways of pancreatic beta-cells and on neural plasticity. Data reported here suggest that clinically relevant doses of GLP-1 and Ex4 may offer some protection against the sensory peripheral neuropathy induced by pyridoxine. Our findings suggest a potential role for these peptides in the treatment of neuropathies, including that associated with type II diabetes mellitus.

Citing Articles

Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.

Olukorode J, Orimoloye D, Nwachukwu N, Onwuzo C, Oloyede P, Fayemi T Cureus. 2024; 16(10):e72080.

PMID: 39574978 PMC: 11579408. DOI: 10.7759/cureus.72080.

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.

Koychev I, Reid G, Nguyen M, Mentz R, Joyce D, Shah S Alzheimers Res Ther. 2024; 16(1):212.

PMID: 39358806 PMC: 11448378. DOI: 10.1186/s13195-024-01573-x.

Vitamin B6 p-JNK/Nrf-2/NF-κB Signaling Ameliorates Cadmium Chloride-Induced Oxidative Stress Mediated Memory Deficits in Mice Hippocampus.

Nasir A, Rahman M, Khan M, Zahid M, Shahab M, Jiao H Curr Neuropharmacol. 2024; 23(1):116-127.

PMID: 39092643 PMC: 11519820. DOI: 10.2174/1570159X22999240730154422.

The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.

Noguchi T, Katoh H, Nomura S, Okada K, Watanabe M Front Neurosci. 2024; 18:1342944.

PMID: 38426018 PMC: 10902060. DOI: 10.3389/fnins.2024.1342944.

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.

Kopp K, Glotfelty E, Li Y, Greig N Pharmacol Res. 2022; 186:106550.

PMID: 36372278 PMC: 9712272. DOI: 10.1016/j.phrs.2022.106550.

References

Satoh F, Beak S, Small C, Falzon M, Ghatei M, Bloom S . Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology. 2000; 141(4):1301-9. DOI: 10.1210/endo.141.4.7420. View

Estall J, Drucker D . Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des. 2006; 12(14):1731-50. DOI: 10.2174/138161206776873671. View

Perry T, Haughey N, Mattson M, Egan J, Greig N . Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002; 302(3):881-8. DOI: 10.1124/jpet.102.037481. View

Perry T, Lahiri D, Sambamurti K, Chen D, Mattson M, Egan J . Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003; 72(5):603-12. DOI: 10.1002/jnr.10611. View

Perry T, Greig N . The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci. 2003; 24(7):377-83. DOI: 10.1016/S0165-6147(03)00160-3. View

During M, Cao L, Zuzga D, Francis J, Fitzsimons H, Jiao X . Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003; 9(9):1173-9. DOI: 10.1038/nm919. View

Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S . Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci. 2004; 110(1):36-43. DOI: 10.1016/j.autneu.2003.11.001. View

Kuntzer T, Antoine J, Steck A . Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004; 30(3):255-68. DOI: 10.1002/mus.20100. View

Perry T, Weerasuriya A, Mouton P, Holloway H, Greig N . Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol. 2004; 190(1):133-44. DOI: 10.1016/j.expneurol.2004.07.013. View

10.

SCHAEPPI U, Krinke G . Pyridoxine neuropathy: correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6. Agents Actions. 1982; 12(4):575-82. DOI: 10.1007/BF01965944. View

11.

Windebank A, Low P, Blexrud M, Schmelzer J, Schaumburg H . Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology. 1985; 35(11):1617-22. DOI: 10.1212/wnl.35.11.1617. View

12.

Albin R, Albers J, GREENBERG H, Townsend J, Lynn R, Burke Jr J . Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology. 1987; 37(11):1729-32. DOI: 10.1212/wnl.37.11.1729. View

13.

Krinke G, FitzGerald R . The pattern of pyridoxine-induced lesion: difference between the high and the low toxic level. Toxicology. 1988; 49(1):171-8. DOI: 10.1016/0300-483x(88)90190-4. View

14.

Xu Y, Sladky J, Brown M . Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology. 1989; 39(8):1077-83. DOI: 10.1212/wnl.39.8.1077. View

15.

Turton M, OShea D, Gunn I, Beak S, Edwards C, Meeran K . A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379(6560):69-72. DOI: 10.1038/379069a0. View

16.

Goke R, Larsen P, Mikkelsen J, Sheikh S . Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995; 7(11):2294-300. DOI: 10.1111/j.1460-9568.1995.tb00650.x. View

17.

Shughrue P, Lane M, Merchenthaler I . Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology. 1996; 137(11):5159-62. DOI: 10.1210/endo.137.11.8895391. View

18.

Wang Y, Perfetti R, Greig N, Holloway H, DeOre K, Montrose-Rafizadeh C . Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest. 1997; 99(12):2883-9. PMC: 508139. DOI: 10.1172/JCI119482. View

19.

Shukitt-Hale B, Mouzakis G, Joseph J . Psychomotor and spatial memory performance in aging male Fischer 344 rats. Exp Gerontol. 1998; 33(6):615-24. DOI: 10.1016/s0531-5565(98)00024-2. View

20.

Greig N, Holloway H, De Ore K, Jani D, Wang Y, Zhou J . Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 1999; 42(1):45-50. DOI: 10.1007/s001250051111. View